simtuzumab

Inside Gilead Sciences’ Active Involvement in Drugs for NASH
Yahoo/Market Realist
Thu, 05/12/16 - 09:44 am
Gilead Sciences
NASH
simtuzumab
GS-4997
GS-9674
Gilead Ends a Phase 2 Study for Antibody
WSJ Online
Wed, 01/6/16 - 08:00 pm
Gilead Sciences
simtuzumab
pancreatic cancer
Can Gilead Sciences Save Key Pipeline Blockbusters from Rivals?
Bidness, ETC
Sat, 01/2/16 - 10:16 am
Gilead Sciences
simtuzumab
NASH
JAK inhibitors
filgotinib
The 3 Most Important Drugs in Gilead Sciences' Pipeline
Motley Fool
Mon, 12/7/15 - 10:53 am
Gilead Sciences
simtuzumab
Zydelig
Sovaldi + velpatasvir
Gilead Sciences: Failed Trial Always a ‘Long Shot’
Barron's
Thu, 09/18/14 - 12:03 pm
Gilead Sciences
clinical trials
pancreatic cancer
simtuzumab
Gilead's oncology contender comes up short in pancreatic cancer
Fierce Biotech
Wed, 09/17/14 - 09:54 am
Gilead Sciences
simtuzumab
pancreatic cancer